相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Jonathan E. Kolitz et al.
LEUKEMIA & LYMPHOMA (2020)
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Mikkael A. Sekeres et al.
BLOOD ADVANCES (2020)
Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
Jorge E. Cortes et al.
BLOOD (2020)
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML
Geoffrey L. Uy et al.
BLOOD (2020)
Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper
Nina Rosa Neuendorff et al.
BLOOD ADVANCES (2020)
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia
Bruno C. Medeiros et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
Lawrence D. Mayer et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience
Sarah Bertoli et al.
CANCER MEDICINE (2019)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
Erik Hulegardh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Bruno C. Medeiros et al.
ANNALS OF HEMATOLOGY (2015)
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Lene Sofie Granfeldt Ostgard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Post-remission therapy for acute myeloid leukemia
Richard F. Schlenk
HAEMATOLOGICA (2014)
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
E. J. Feldman et al.
LEUKEMIA RESEARCH (2012)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Sabine Kayser et al.
BLOOD (2011)
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells
Hyun Pyo Kim et al.
EXPERIMENTAL HEMATOLOGY (2011)
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Eric J. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
Elias Jabbour et al.
CANCER (2010)
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Boglarka Gyurkocza et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
Wah-Seng Lim et al.
LEUKEMIA RESEARCH (2010)
Secondary acute myeloid leukemia - a single center experience
T. Szotkowski et al.
NEOPLASMA (2010)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Paul Tardi et al.
LEUKEMIA RESEARCH (2009)
Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data
DA Revicki et al.
QUALITY OF LIFE RESEARCH (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comorbidity considerations in geriatric oncology research
JW Yates
CA-A CANCER JOURNAL FOR CLINICIANS (2001)
分享论文
